{
  "docId": "019dd923-622b-71dc-a6da-84595e2c37a3",
  "docSlug": "08680a75fcb3",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 63,
  "pageCount": 74,
  "prevPage": 62,
  "nextPage": 64,
  "slideType": "expose_contradiction",
  "function": "expose_gap",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The chart uses a visual callout to quantify the 132 percentage point gap between Pfizer and the S&P 500.",
  "elementsJson": [
    "headline_text",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/63",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-63",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.1,
        "x": 0.88,
        "y": 0.4
      },
      "kind": "callout",
      "text": "132pts of underperformance",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73036de7-477d-459b-846f-2dd2c5b0fb58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.95,
        "x": 0.04,
        "y": 0.155
      },
      "kind": "chart",
      "text": "Pfizer Total Shareholder Returns",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9c0206f-1c76-4faf-b2e7-c50509a5633d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Total Shareholder Return: 132pts",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a396-79a33abb0b5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.02,
        "y": 0.98
      },
      "kind": "source-note",
      "text": "Source: Bloomberg. Market data as of October 4, 2024.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c60a1ccd-7f24-41ec-b9dc-a998045788b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 1,
        "x": 0,
        "y": 0.9
      },
      "kind": "title",
      "text": "Pfizer has underperformed over the last five years.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30688270-e3eb-47ed-b6b5-4c09e625f129",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "The Company's TSR Since 2019 Has Been Poor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edf2152d-ec31-479a-9259-89bb1e738a0e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "5d852cf5-0f52-4a35-85db-07eeb9775d59",
      "evidence": "Comparing Pfizer performance against S&P 500 and NYSE Arca Pharma Index",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 73,
      "from": 62,
      "beatId": "a59926c3-5c53-408e-b52d-295dfb9b624a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes potential solutions, including focusing on R&D and innovation, improving capital allocation, and holding management accountable.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07",
      "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.",
      "position": 0,
      "objective": "What are the costs of inaction for Pfizer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 71,
      "from": 11,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f",
      "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.",
      "position": 1,
      "objective": "How can Pfizer improve its performance?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    },
    {
      "to": 73,
      "from": 62,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c59431c8-0af0-4e90-9758-ec528e713b8a",
      "evidence": "The document highlights potential areas for improvement and growth.",
      "position": 2,
      "objective": "What are the potential quick wins and big bets for Pfizer?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}